Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06373159
Other study ID # 22643
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date April 10, 2024
Est. completion date September 30, 2024

Study information

Verified date May 2024
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational study in which data already collected from people with sepsis (blood poisoning) and/or disseminated intravascular coagulation (DIC) are studied. In observational studies, only observations are made without participants receiving any advice or changes to their healthcare. DIC is a serious blood disorder that can cause clots throughout the body, blocking blood vessels. People who have sepsis or cancer are at a higher risk of developing DIC. To find a treatment that works well for people with DIC associated with sepsis, it is important to know about its occurrence, treatments people receive, and their outcomes. Japan is the only country that has officially approved medicines for DIC including a few newer medicines that prevent extensive blood clotting. In this study, researchers will assess patient data from a hospital database in Japan. The main purpose of this study is to learn more about how many adults develop DIC related to sepsis, thrombocytopenic sepsis (sudden decrease in the number of platelets in the blood), or septic shock (dangerously low blood pressure) in Japan every year. To learn about this, researchers will collect the following information: - The number of participants who developed DIC 14 days, 21 days and 28 days after their sepsis diagnosis - The grading scores given to the participants which are used to assess the likelihood, cause, severity, treatment plan, and outcome of DIC (including scores called JAAM, ISTH, MHLW, and/or SOFA scores) - The number of days between diagnosis of sepsis and the beginning of DIC Researchers will study the data collected between June 2018 and June 2023. The data will come from TXP Medical, which collects data through the hospital health information system of 7 selected hospitals for this study across Japan. In this study, only available data from routine care are collected.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 5740
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Sepsis patient cohort - Sepsis patients - Age =18 years - Subgroups: - Sepsis with thrombocytopenia patient cohort - Septic shock patient cohort - Sepsis-associated DIC patient cohort - DIC patients in sepsis patient cohort - Subgroups: - Organ failure: kidney (Serum creatinine (SCr) < 1.2 mg/dl and = 1.2 mg/dl) - Organ failure: liver (bilirubin < 1.2 mg/dl and = 1.2 mg/dl) - Organ failure: cardiovascular (with and without catecholamine or vasopressin) - With low molecular weight (LMW) heparins, unfractionated heparins, and both - With and without DIC treatment - Priority 1_Anticoagulants specifically used in Japan (recombinant antithrombin, recombinant thrombomodulin, human anti-thrombin III) - Priority 1 + Priority 2_Drugs for sepsis-associated DIC (LMW heparins, unfractionated heparins, protease inhibitors) - Priority 1 + Priority 2 + Priority 3_antibiotics (antifungals), and/or steroids - Non-sepsis-associated DIC patient cohort - Hematopoietic malignant tumor patients - DIC patients - Age =18 years Exclusion Criteria: - Sepsis patient cohort: None - Sepsis-associated DIC patient cohort: None - Non-sepsis-associated DIC patient cohort: Sepsis patients

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No study intervention
Retrospective observational study using Real World Data (RWD) in Japan without study intervention

Locations

Country Name City State
Japan Bayer Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of DIC assessed at 14 days, 21 days and 28 days of the patient follow up DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Primary Distribution of JAAM DIC score The Japanese Association for Acute Medicine (JAAM) DIC scoring algorithm includes a number of variables but in addition specific criteria for evidence of a Systemic Inflammatory Response Syndrome (SIRS). JAAM DIC score >= 4 supports a diagnosis of DIC. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Primary Distribution of ISTH DIC score The International Society on Thrombosis Haemostasis (ISTH) DIC score is a simple scoring system produced by the ISTH group for the diagnosis of DIC depending on the Platelet count, the PT, the fibrinogen level and critically the FDP/D-Dimer results. A total score of =5 = DIC as long as the score is associated with a clinical disorder known to cause DIC. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Primary Distribution of MHLW DIC score The Japanese Ministry of Health, Labor and Welfare (MHLW) DIC score is a scoring system for the diagnosis of overt DIC. MHLW DIC score =7 is defined as DIC. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Primary Distribution of SOFA score The Sequential Organ Failure Assessment (SOFA) score is a scoring system based on performance of respiratory, coagulation, liver, cardiovascular, central nervous system, and kidney. The higher the SOFA score, the higher the likely mortality. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Primary Days from sepsis diagnosis to the onset of DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per clinical characteristics Clinical characteristics (e.g., demographics, comorbidities, medical history) in patients with sepsis, thrombocytopenic sepsis and septic shock, respectively; in patients with sepsis in different definitions (diagnosis codes, laboratory values, and procedure codes); at the onset of DIC in patients who developed sepsis-associated DIC. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per DIC treatment patterns in patients with sepsis-associated DIC following the onset of DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Incidence rates of clinical outcomes assessed in patients with sepsis-associated DIC Clinical outcomes are assessed at 14 days, 28 days, 60 days, 183 days, 365 days (1 year) and 730 days (2 years) of follow up. Clinical outcomes include thrombosis, major bleeding, organ failures, death, ICUs admission during the index hospitalization, discharge during the index hospitalization, length of index hospitalization. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Cumulative incidences of clinical outcomes assessed in patients with sepsis-associated DIC Clinical outcomes are assessed at 14 days, 28 days, 60 days, 183 days, 365 days (1 year) and 730 days (2 years) of follow up. Clinical outcomes include thrombosis, major bleeding, organ failures, death, ICUs admission during the index hospitalization, discharge during the index hospitalization, length of index hospitalization. DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per clinical characteristics in subgroup of patients who developed sepsis-associated DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per treatment patterns in subgroup of patients who developed sepsis-associated DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Incidence rates of clinical outcomes in subgroup of patients who developed sepsis-associated DIC Clinical outcomes include thrombosis, major bleeding, organ failures, death, ICUs admission during the index hospitalization, discharge during the index hospitalization, length of index hospitalization. Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per clinical characteristics after the onset of DIC in patients with non-sepsis-associated DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Number of participants per treatment patterns after the onset of DIC in patients with non-sepsis-associated DIC DIC: disseminated intravascular coagulation Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
Secondary Incidence rates of clinical outcomes after the onset of DIC in patients with non-sepsis-associated DIC Clinical outcomes include thrombosis, major bleeding, organ failures, death, ICUs admission during the index hospitalization, discharge during the index hospitalization, length of index hospitalization. Retrospective analysis of real world data between 01 JUN 2018 and 01 JUN 2023
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3